Exelixis, Inc. (EXEL) Soars to 52-Week High, Time to Cash Out?

Exelixis (EXEL) has surged to a 52-week high of $49.62, marking a 30.2% year-to-date gain and significantly outperforming its sector, driven by consistent earnings beats and robust future growth projections. The company reported Q1 2025 EPS of $0.62 against a $0.42 consensus, with FY2025 EPS expected to rise 30.5% to $2.61. Despite its recent rally, EXEL maintains a Zacks Rank #2 (Buy) and its 16.6x forward P/E remains below the peer average, suggesting potential for continued upside within the favorable Medical - Biomedical and Genetics industry.

Analysis

Exelixis (EXEL) has demonstrated significant market outperformance, reaching a new 52-week high of $49.62 and delivering a 30.2% year-to-date gain, in stark contrast to the negative returns of the broader Zacks Medical sector (-5.1%) and its direct industry (-4.2%). This momentum is fundamentally driven, evidenced by a consistent history of positive earnings surprises over the last four quarters, including a recent report of $0.62 EPS against a $0.42 consensus. The forward-looking outlook remains robust, with analysts projecting 30.5% EPS growth for the current fiscal year and an additional 16.13% for the next. Despite the stock's rally, its valuation presents a compelling case; it trades at a forward P/E of 16.6x, below the peer average of 19.4x, and boasts an attractive PEG ratio of 0.79. While its trailing price-to-cash-flow multiple of 22.5x is elevated above its peer group's 14.6x average, the combination of strong 'A' grades for Growth and Momentum, a #2 (Buy) Zacks Rank fueled by rising estimates, and positive industry tailwinds suggests the rally is well-supported.

Key Decisions for Investors

• Given the strong earnings growth trajectory and a forward P/E that remains below the industry average, investors may view the recent 52-week high as a confirmation of fundamental strength rather than an immediate signal to sell.
• The combination of a #2 (Buy) Zacks Rank and top-tier 'A' scores for Growth and Momentum suggests that maintaining or initiating a position could be warranted for those aligned with a growth investment style.
• While the forward-looking metrics are positive, investors should monitor the elevated trailing price-to-cash-flow ratio of 22.5x as a potential risk factor, ensuring that future cash flow generation justifies this premium.